Therapeutic | Glembatumumab |
Target | GPNMB |
Heavy Chain | QVQLQESGPGLVKPSQTLSLTCTVSGGSISSFNYYWSWIRHHPGKGLEWIGYIYYSGSTYSNPSLKSRVTISVDTSKNQFSLTLSSVTAADTAVYYCARGYNWNYFDYWGQGTLVTVSS |
Light Chain | EIVMTQSPATLSVSPGERATLSCRASQSVDNNLVWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb ADC |
Isotype | G2 |
Highest Clinical Trial (August '23) | Phase-III |
Estimated Status (August '23) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 2015 |
INN Year Recommended | 2016 |
Companies Involved | CuraGen Corporation%3BCelldex Therapeutics Inc%3BNational Cancer Institute %28USA%29 |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Brain cancer%3BBreast cancer%3BMalignant melanoma%3BOsteosarcoma%3BSquamous cell cancer%3BUveal melanoma |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]